191 related articles for article (PubMed ID: 36161282)
21. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
23. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y
Oncology; 2020; 98(1):48-52. PubMed ID: 31487733
[TBL] [Abstract][Full Text] [Related]
24. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
26. Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
Anticancer Res; 2018 Oct; 38(10):5975-5981. PubMed ID: 30275228
[TBL] [Abstract][Full Text] [Related]
27. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
[TBL] [Abstract][Full Text] [Related]
28. Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Chan DY; Syn NL; Yap R; Phua JN; Soh TI; Chee CE; Nga ME; Shabbir A; So JB; Yong WP
J Gastrointest Surg; 2017 Mar; 21(3):425-433. PubMed ID: 27981493
[TBL] [Abstract][Full Text] [Related]
29. INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS: STUDY PROTOCOL OF A PHASE II TRIAL.
Ramos MFKP; Pereira MA; Charruf AZ; Victor CR; Gregorio JVAM; Alban LBV; Moniz CMV; Zilberstein B; Mello ES; Hoff PMG; Ribeiro Junior U; Dias AR
Arq Bras Cir Dig; 2023; 36():e1744. PubMed ID: 37466566
[TBL] [Abstract][Full Text] [Related]
30. A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Lu S; Yang ZY; Yan C; Liu WT; Ni ZT; Yao XX; Hua ZC; Feng RH; Zheng YN; Wang ZQ; Sah BK; Chen MM; Zhu ZL; He CY; Li C; Yan M; Zhu ZG
Future Oncol; 2022 Mar; 18(10):1175-1183. PubMed ID: 35114800
[TBL] [Abstract][Full Text] [Related]
31. Autologous CIK cells combined with chemotherapy as the first-line treatment for locally advanced or metastatic gastric cancer is safe and feasible.
Ma X; Peng L; Wang J; Gao L; Zhang W; Lu X; Liu J; Yang L
Front Immunol; 2023; 14():1267369. PubMed ID: 38022664
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial.
Takahashi N; Kanda M; Yoshikawa T; Takiguchi N; Fujitani K; Miyamoto K; Ito Y; Takayama O; Imano M; Mitsumori N; Sakamoto J; Morita S; Kodera Y
Gastric Cancer; 2018 Nov; 21(6):1014-1023. PubMed ID: 29536296
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer.
Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Shinkai M; Imano M; Hiraki Y; Momose K; Kato H; Shiraishi O; Yasuda A; Tsubaki M; Nishida S; Yasuda T
Langenbecks Arch Surg; 2022 May; 407(3):975-983. PubMed ID: 34988644
[TBL] [Abstract][Full Text] [Related]
35. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J
Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Dai X; Zhang X; Wang C; Jiang J; Wu C
Oncotarget; 2017 May; 8(18):30495-30501. PubMed ID: 27911869
[TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan.
Kono K; Yong WP; Okayama H; Shabbir A; Momma T; Ohki S; Takenoshita S; So J
Gastric Cancer; 2017 Mar; 20(Suppl 1):122-127. PubMed ID: 27766496
[TBL] [Abstract][Full Text] [Related]
38. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
Gou M; Zhang Y; Wang Z; Qian N; Dai G
Invest New Drugs; 2024 Apr; 42(2):171-178. PubMed ID: 38347177
[TBL] [Abstract][Full Text] [Related]
39. Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol.
Vatandoust S; Bright T; Roy AC; Watson D; Gan S; Bull J; Abbas MN; Karapetis CS
BMJ Open; 2019 May; 9(5):e026732. PubMed ID: 31061042
[TBL] [Abstract][Full Text] [Related]
40. Intraperitoneal Paclitaxel Combined with S-1 Plus Oxaliplatin for Advanced Gastric Cancer with Peritoneal Metastasis: a Phase I Study.
Kim DW; Seo WJ; Youn SI; Jee YS; Jang YJ; Kim JH;
J Gastric Cancer; 2021 Dec; 21(4):418-425. PubMed ID: 35079443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
